Table 2.
GRADE summary of human mesenchymal stem cell transplantation for cerebral palsy.
| Outcome | Absolute effect estimates (95% CI) | Relative effect (95% CI) | Participants (studies) | Evidence (GRADE)† | Comments | |
|---|---|---|---|---|---|---|
| Control | hMSC therapy | |||||
| GMFM | — | SMD 1.1 higher (0.66 to 1.53 higher) | — | 163 (3) |
⊕⊕⊕⊕
High |
hMSC therapy has important benefit in increasing GMFM. |
| CFA | — | SMD 1.3 higher (0.71 to 1.90 higher) | — | 96 (3) |
⊕⊕⊕⊕
Moderate |
hMSC therapy has important benefit in increasing CFA. |
| Upper respiratory infection | 468 per 1000 | 417 per 1000 (267 to 651) Difference: 51 fewer per 1000 (201 to 183) |
RR 0.89 (0.57 to 1.39) | 93 (2) |
⊕⊕⊕○
Moderate |
hMSC therapy did not increase AE of upper respiratory infection. |
| Diarrhea | 298 per 1000 | 241 per 1000 (125 to 468) Difference: 57 fewer per 1000 (173 to 170) |
RR 0.81 (0.42 to 1.57) | 93 (2) |
⊕⊕⊕○
Moderate |
hMSC therapy did not increase AE of diarrhea. |
| Constipation | 106 per 1000 | 65 per 1000 (16 to 260) Difference: 41 fewer per 1000 (90 to 153) |
RR 0.61 (0.15 to 2.44) | 93 (2) |
⊕⊕⊕○
Moderate |
hMSC therapy did not increase AE of constipation. |
†High: we are confident that the true effect of outcomes lies close to the estimate of the effect. Moderate: we are moderately confident that the assessed effects and the true effect are likely to be close to the assessed effects. CI: confidence interval; RR: risk ratio; AE: adverse event; SMD: standardized mean difference.